Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine

2008155 citationsJournal Articlegold Open Access

Authors

Benoı̂t Baras · GlaxoSmithKline (Belgium)

Koert J. Stittelaar · Viroclinics Biosciences (Netherlands)

James H. Simon · Viroclinics Biosciences (Netherlands)

Robert J. M. M. Thoolen

Sally Mossman · GlaxoSmithKline (Belgium)

F.H.M. Pistoor · Viroclinics Biosciences (Netherlands)

Geert van Amerongen · Viroclinics Biosciences (Netherlands)

Abstract

These protection data in a stringent challenge model in association with an excellent clinical profile highlight the potential of this adjuvanted H5N1 candidate vaccine as an effective tool in pandemic preparedness.

Topics & Keywords

Influenza Virus Research Studies Animal Disease Management and Epidemiology Respiratory viral infections research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PLoS ONE

Volume 3, Issue 1, pp. e1401-e1401

DOI: 10.1371/journal.pone.0001401

Field-Weighted Citation Impact: 17.65